Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease, Metabolic Disorder, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AGER/RAGE drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AGER ECD-Fc Fusion (V-domain containing) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View AGER Products |
| Gene Delivery | AGER Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction. Ideal for internalization assays. |
View AGER Products |
| Benchmark Ab | Anti-AGER Neutralizing Antibody Recombinant positive control for ligand blocking studies. |
View AGER Products |
| Validator | AGER siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View AGER Products |
| Primary Ligand | HMGB1 (High Mobility Group Box 1) Primary Damage-Associated Molecular Pattern (DAMP) ligand for AGER. |
View HMGB1 Products |
| Pathway Partner | TLR4 (Toll-Like Receptor 4) Synergistic signaling node in inflammatory response. |
View TLR4 Products |
| Tumor Marker | S100A9 Pro-inflammatory ligand overexpressed in tumor microenvironments. |
View S100A9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multiligand Binding Selectivity (HMGB1 vs AGEs vs S100) | Domain-specific ECD constructs (V-type Ig domain vs Full ECD) with Theoretical MW verification by Mass Spec. |
| Cross-species Diabetes Model Evaluation | Human/Mouse/Cyno AGER ortholog proteins available with >95% purity, Sequence Verified for epitope conservation. |
| Soluble RAGE (sRAGE) Competition | Matched sRAGE vs Full-length AGER protein pairs for ELISA development. |
| Internalization Efficiency (ADC Development) | Lentivirus-delivered Full-length AGER in HEK293 background for live-cell imaging and pH-dependent trafficking assays. |
| False Positives in Binding Assays | AGER-specific siRNA included for target-specificity validation in competition studies. |
Live AGER R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- View RAGE Clinical Trials
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for AGER/RAGE therapeutics is intensifying, with major players shifting focus from broad anti-inflammatory approaches to precision modulation of specific ligand interactions. As first-generation small molecule inhibitors (V-domain blockers) and soluble decoy receptors reach Phase II for diabetic complications and Alzheimer's disease, the next wave of R&D is targeting tumor-associated AGER signaling in immuno-oncology and combination therapies with immune checkpoint inhibitors. The modern landscape also includes acute inflammation (ARDS, sepsis) and oncology tumor microenvironments, with engineered monoclonal antibodies and recombinant decoy receptors (sRAGE) aiming for selective V-domain blockade to inhibit pathological HMGB1/S100 signaling without disrupting basal homeostasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Decoy Receptor (sRAGE-Fc) | Novo Nordisk, Sanofi | Diabetic Nephropathy, Atherosclerosis | Quantitative ligand binding (HMGB1/AGEs) with high-purity ECD-Fc standards. |
| Small Molecule Inhibitor | vTv Therapeutics, Pfizer, Academic Consortia | Alzheimer's Disease, Inflammation, Solid Tumors | V-domain specific protein for SPR screening; Mutant variants for structure-activity studies. |
| Anti-AGER mAb | Emerging Biotech | Solid Tumors (AGER+), Diabetic Nephropathy, Sepsis | Internalization assays using Lentivirus-stable cell lines; Cross-species cyno binding. |
| ADC | Oncology-Focused Biotech | Triple-Negative Breast Cancer, Lung Cancer | Endotoxin-controlled antigen (<1EU/ug) for sensitive cell-based cytotoxicity assays. |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
1. Ligand Selectivity Binding
- Scientific Need: AGER binds HMGB1 via V-type Ig domain and AGEs via C-type domains. Best-in-class drugs must clarify broad vs selective inhibition.
- TarMart Assay Solution: Domain-specific ECD constructs (V-domain only vs V+C1 vs Full ECD) for SPR/BLI; biotinylated ligand panel (HMGB1, S100A8, S100A9, CML-AGEs) for competitive ELISA.
2. Internalization Efficiency for ADC
- Scientific Need: For anti-AGER ADC development, internalization rate and lysosomal targeting must be validated.
- TarMart Assay Solution: Lentivirus full-length AGER stable cell lines (HEK293 or MCF-7) for live-cell imaging; pH-sensitive fluorescent antibodies for surface vs endocytic pool distinction.
3. Cross-species Reactivity
- Scientific Need: Preclinical models (mouse, cyno) require validated ortholog binding.
- TarMart Assay Solution: Human/Mouse/Cyno AGER ECD trio (sequence verified, >95% purity); species-specific antibodies for PK/PD free drug assays.
4. Splice Variant Discrimination
- Scientific Need: Distinguish membrane-bound vs soluble sRAGE for decoy receptor therapy.
- TarMart Assay Solution: Transmembrane deletion mutant (mimicking sRAGE) paired with full-length protein for sandwich ELISA development.
5. High-Concentration Stability for Sub-Q
- Scientific Need: Subcutaneous injection requires >100 mg/mL with low viscosity; avoid V-domain hydrophobic aggregation.
- TarMart Assay Solution: High-concentration formulation compatibility testing proteins; Cys-to-Ser mutants to eliminate free thiol-induced aggregation.